COLLABORATIVE ARRANGEMENTS (Details 2) (USD $)	3 Months Ended		9 Months Ended
	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012
Information related to collaborative arrangements
Revenues	$ 439,000	$ 1,430,000	$ 3,110,000	$ 129,960,000
GSK
Information related to collaborative arrangements
Revenues	415,000	1,430,000	3,059,000	4,291,000
GSK | MABA
Information related to collaborative arrangements
Potential future contingent payments receivable	363,000,000		363,000,000
Long-acting beta agonist (LABA) collaboration | GSK
Information related to collaborative arrangements
Number of combination products			2
Portion of potential milestone payments that became payable due to the launch of BREO ELLIPTA			30,000,000
Registrational milestone fee paid			40,000,000
Long-acting beta agonist (LABA) collaboration | GSK | Maximum
Information related to collaborative arrangements
Obligation for milestone payments	180,000,000		180,000,000
Portion of potential milestone payments that could be payable during the remainder of 2013	70,000,000		70,000,000
Royalty rate for combination products	10.00%
Long-acting beta agonist (LABA) collaboration | GSK | LABA collaboration
Information related to collaborative arrangements
Royalty rate for first level of annual global net sales (as a percent)			15.00%
Annual global sales level used to determine royalty rate			3,000,000,000
Royalty rate for sales above first level of annual global net sales (as a percent)			5.00%
Revenues		907,000	1,814,000	2,722,000
2004 Strategic alliance | GSK | MABA
Information related to collaborative arrangements
Number of preclinical MABA compounds discovered			6
Revenues	415,000	523,000	1,245,000	1,569,000
2004 Strategic alliance | GSK | MABA | Minimum
Information related to collaborative arrangements
Number of products which Company is obligated to use diligent efforts to discover after license of a program			1
2004 Strategic alliance | GSK | MABA containing '081 | Maximum
Information related to collaborative arrangements
Potential contingent payments that the Company could receive in respect to single-agent and combination medicines	250,000,000		250,000,000
2004 Strategic alliance | GSK | MABA containing '081 - single-agent
Information related to collaborative arrangements
Annual global sales level used to determine royalty rate			3,500,000,000
Royalty rate for sales above first level of annual global net sales (as a percent)			7.50%
2004 Strategic alliance | GSK | MABA containing '081 - single-agent | Minimum
Information related to collaborative arrangements
Royalty rate for first level of annual global net sales (as a percent)			10.00%
2004 Strategic alliance | GSK | MABA containing '081 - single-agent | Maximum
Information related to collaborative arrangements
Royalty rate for first level of annual global net sales (as a percent)			20.00%
Potential contingent payments that the Company could receive	125,000,000		125,000,000
2004 Strategic alliance | GSK | MABA containing '081 - combination product
Information related to collaborative arrangements
Royalty rate for combination products as a percentage of the rate applied to single products			70.00%
2004 Strategic alliance | GSK | MABA containing additional MABA | Maximum
Information related to collaborative arrangements
Potential future contingent payments receivable	129,000,000		129,000,000
2004 Strategic alliance | GSK | MABA containing additional MABA - single-agent
Information related to collaborative arrangements
Annual global sales level used to determine royalty rate			3,500,000,000
Royalty rate for sales above first level of annual global net sales (as a percent)			10.00%
2004 Strategic alliance | GSK | MABA containing additional MABA - single-agent | Minimum
Information related to collaborative arrangements
Royalty rate for first level of annual global net sales (as a percent)			10.00%
2004 Strategic alliance | GSK | MABA containing additional MABA - single-agent | Maximum
Information related to collaborative arrangements
Royalty rate for first level of annual global net sales (as a percent)			15.00%
2004 Strategic alliance | GSK | MABA containing additional MABA - combination product
Information related to collaborative arrangements
Royalty rate for combination products as a percentage of the rate applied to single products			50.00%
Common stock purchase agreement | GSK
Information related to collaborative arrangements
Company's stock purchased by related party (in shares)			3,374,497
Company's stock purchased by related party			$ 121,100,000